the website featuring small cap undervalued stocks which move 100% to 200% in a day, presents Surging Volumes with Positive Closing at NASDAQ Healthcare Sector from PSL are LXRX, NBIX, INHX, ALTH and AKRX.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) reported a gain of 1.78%, closing the day at $1.72 with the overall traded volume of 1.43 million shares for the day. Its market capitalization is $580.34 million. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) jumped 6.91%, closing the day at $8.04 with the overall traded volume of 1.27 million shares for the day. Its market capitalization is $440.93 million. Neurocrine Biosciences, Inc. engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.
Inhibitex, Inc. (NASDAQ: INHX) gained 10.44%, closing the day at $2.01 with the overall traded volume of 1.08 million shares for the day. Its market capitalization is $124.89 million. Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections, primarily shingles and chronic infections caused by hepatitis C virus (HCV). Its antiviral product candidates include FV-100, an orally available nucleoside analogue prodrug, which is in Phase II trials for the treatment of herpes zoster or shingles; and INX-189, a HCV nucleoside polymerase inhibitor that has completed preclinical studies for the treatment of chronic hepatitis C infection.
Allos Therapeutics, Inc. (NASDAQ: ALTH) increased 1.11%, closing the day at $4.56 with the overall traded volume of 1.06 million shares for the day. Its market capitalization is $480.32 million. Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing anti-cancer therapeutics. It is developing FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Akorn, Inc. (NASDAQ: AKRX) surged 5.91%, closing the day at $4.66 with the overall traded volume of 1.06 million shares for the day. Its market capitalization is $436.83 million. Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States. The company's Ophthalmic segment markets diagnostic products, including mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, and angiography dyes, which are used in the office setting.
About PennyStockLive.Com (http://www.pennystocklive.com)
PennyStockLive.com focuses due diligence efforts on stocks that cost less than $5.00 per share. The site finds an array of companies on the NASDAQ, NYSE, AMEX and on occasion OTCBB. Whether it is a downtrend on the main markets that they witness or bullish sentiment that occurs, PennyStockLive.com provides both short trading tips as well as regular equity buying suggestions.
To Receive Stocks That Move 50% to 100% in Few Days Sign up at: http://www.PennyStockLive.com
PennyStockLive.com offers these services along with the following for small, medium, and large cap investors:
Buy and sell recommendations
Daily Chart Alerts
The assembled information disseminated by PennyStockLive.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. TryPennyStocks.com does expect that investors will buy and sell securities based on information assembled and presented in TryPennyStocks.com. PLEASE always do due diligence and consult a financial advisor.
Disclaimer and forwarding looking statements
Please read PennyStockLive.com disclaimer at PennyStockLive.com/disclaimer.